TCM
IDXX icon

Thames Capital Management’s Idexx Laboratories IDXX Stock Holding History

Thames Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,007
Closed -$6.02M – 40
2022
Q1 		$6.02M Buy
+11,007
New +$5.79M 1.27% 33

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Thames Capital Management's IDXX Position: Q2 2022 in Review

Thames Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2022, closing a stake of 11,007 shares — an estimated $6.02M sold.

Thames Capital Management first reported a position in IDXX in Q1 2022 and held it in 1 quarter. The position peaked at $6.02M in Q1 2022. 956 funds tracked by Wall St. Rank hold IDXX as of Q2 2022.

  • Thames Capital Management reported no remaining Idexx Laboratories position as of Q2 2022 after selling out during the quarter.
  • Thames Capital Management sold 11,007 Idexx Laboratories shares in Q2 2022, an estimated $6.02M.
  • Thames Capital Management first reported a position in Idexx Laboratories in Q1 2022 and held it in 1 quarter.
  • Thames Capital Management's Idexx Laboratories position peaked at $6.02M in Q1 2022.
  • 956 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2022.

Based on Thames Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.